Pegylated-Interferon-Alpha 2a in Clinical Practice: How to Manage Patients Suffering from Side Effects
February 2011
in “
Expert Opinion on Drug Safety
”
Studysummary This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document reviewed the management of side effects in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha2a and ribavirin. It reported that 80% of patients experience side effects, including flu-like symptoms, hematological changes, and neuropsychiatric disturbances, with 20-30% affected by depression. Management strategies include dose modifications and the use of growth factors like erythropoietin or G-CSF for hematologic side effects, and SSRIs for depression. The review also suggested that the addition of protease inhibitors to therapy could shorten treatment duration and reduce side effects, improving adherence. It stressed the importance of managing side effects to achieve sustained virologic response and noted that future treatments with protease inhibitors may change the treatment landscape for HCV infection.
